Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke

Not Applicable

Not yet recruiting

• Conditions: Acute Ischemic Stroke

• Registration Number: NCT03669653
• Lead Sponsor: Yi Yang

Brief Summary

he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Detailed Description

In this study, 912 cases of ischemic stroke in 48 hours were included in 5 centers in China according to the principle of random, double-blind and parallel control .The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days .The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day, 7 days in a row . Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning therapy.

Study Timeline

• Study First Submitted: 2018-08-27
• Study First Submitted QC: 2018-09-11
• Study First Posted: 2018-09-13
• Status Verified: 2024-02
• Last Update Submitted: 2024-10-01
• Last Update Posted: 2024-10-02
• Study Start: 2025-06-17
• Primary Completion: 2026-09-20
• Study Completion: 2026-09-20

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 912

Inclusion Criteria

• 1）Age≥18 years, < 80 years, regardless of sex；
• 2）Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 12 hours of stroke onset
• 3）Baseline NIHSS score>5, and≤25 ；
• 4）GCS score ≥8；
• 5）Signed and dated informed consent is obtained

Exclusion Criteria

• 1. Patients with suspected posterior circulation infarction；
• 2. Patients who undergo thrombolytic therapy or endovascular treatment；
• 3. mRS≥2 score before the onset of the disease；
• 4. Double upper limbs or lower limbs paralysis was found in this case；
• 5）Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on；
• 6. Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain；
• 7. Treated blood pressure ≤90mmHg/60mmHg or≥180mmHg/100mmHg；
• 8. Severe organ dysfunction or failure；
• 9. Persons suffering from severe hematological diseases or severe coagulation disorder dysfunction；
• 10. Those who had a history of severe trauma or had major surgery within 6 months prior to admission；
• 11. The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb；Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc；
• 12. Pregnant or lactating women；
• 13. Previous remote ischemic conditioning therapy or similar treatment；
• 14. Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons；
• 15. Severe hepatic and renal dysfunction
• 16. Unwilling to be followed up or treated for poor compliance；
• 17. He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission；
• 18. Other conditions that the researchers think are not suitable for the group.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Proportion of patients with Modified Rankin Scale (mRS) Score 0-2	3 months	The primary outcome measure of efficacy is the modified Rankin Scale (mRS) dichotomized to define good functional outcome as mRS 0-2 at 90 days.score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.

Secondary Outcome Measures

Name	Time	Method
NIHSS Score at end of 7th day of treatment	7 days	NIHSS Score at end of 7th day of treatment
Changes of hematological indicators	48h; 7days	The changes of hematological indicators (inflammatory cytokine,et al.) between the first 48h and end of 7th day of treatment.
mRS Score at end of 7th day of treatment	7 days	mRS Score at end of 7th day of treatment
Barthel Index at end of 7th day of treatment	7 days	Barthel Index at end of 7th day of treatment

Trial Locations

Locations (1)

First Hospital of Jilin University; 🇨🇳 Changchun, Jilin, China